For breast cancer, PDPN+-CAFs tended to result in a more malignant pathological status and could facilitate immunosuppression and disease progression, which is consistent with the finding of this meta-analysis study and the findings of PDPN functions in multiple types of solid tumors (Du et al., 2023; Yamaguchi et al., 2021). The gene discussed is PDPN; the disease is breast cancer.